TSS
NAUT icon

Two Sigma Securities’s Nautilus Biotechnolgy NAUT Stock Holding History

Two Sigma Securities’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,239
Closed -$31.7K – 2000
2025
Q4 		$31.7K Buy
+16,239
New +$26.6K ﹤0.01% 1120

Other funds holding NAUT

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ST
Sentinel Trust Houston, Texas $1.13B AUM 24.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Two Sigma Securities's NAUT Position: Q1 2026 in Review

Two Sigma Securities sold out of Nautilus Biotechnolgy (NAUT) in Q1 2026, closing a stake of 16,239 shares — an estimated $31.7K sold.

Two Sigma Securities first reported a position in NAUT in Q4 2025 and held it in 1 quarter. The position peaked at $31.7K in Q4 2025. 81 funds tracked by Wall St. Rank hold NAUT as of Q1 2026.

  • Two Sigma Securities reported no remaining Nautilus Biotechnolgy position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Securities sold 16,239 Nautilus Biotechnolgy shares in Q1 2026, an estimated $31.7K.
  • Two Sigma Securities first reported a position in Nautilus Biotechnolgy in Q4 2025 and held it in 1 quarter.
  • Two Sigma Securities's Nautilus Biotechnolgy position peaked at $31.7K in Q4 2025.
  • 81 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.